Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions

US8889709B2 · kind B2 · utility

Assignee

• PROBIODRUG AG · DE

Inventors

• Hans-Ulrich Demuth · Halle (Saale), DE
• Stephan Schilling · Halle (Saale), DE
• Michael Wermann · Halle (Saale), DE
• Holger Cynis · Dohnsen, DE
• Astrid Kehlen · Halle (Saale), DE
• Daniel Friedrich · Halle (Saale), DE
• Torsten Hoffmann · Weil am Rhein, DE
• Kathrin Gans · Halle (Saale), DE
• Jens-Ulrich Rahfeld · Lieskau, DE
• Ulrich Heiser · Halle (Saale), DE
• Michael Almstetter · Martinsried, DE
• Robert Sommer · Halle (Saale), DE
• Ulf-Torsten Gaertner · Halle (Saale), DE
• Antje Hamann · Schkopau, DE
• Michael Thormann · Martinsried, DE
• Andreas Treml · Martinsried, DE

Key dates

• Filing date: Sep 4, 2009
• Grant date: Nov 18, 2014
• Expiry date: Feb 26, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/104
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.